XML 23 R43.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Related Party Transactions (Details Textual) (USD $) | 0 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | 6 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 20, 2014 | Apr. 30, 2012 | Jun. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jul. 18, 2014 Subsequent Event [Member] | Apr. 30, 2012 Series A Preferred Stock [Member] | Dec. 31, 2013 Series A Preferred Stock [Member] | Jun. 30, 2014 Common Stock [Member] | Dec. 31, 2013 Common Stock [Member] | Dec. 31, 2012 Common Stock [Member] | Jun. 30, 2014 Medeor [Member] | May 19, 2014 Placement Agent [Member] Drugs | Dec. 06, 2011 Placement Agent [Member] | Oct. 24, 2013 Placement Agent [Member] | Jun. 30, 2014 Placement Agent [Member] | Dec. 31, 2013 Placement Agent [Member] | Dec. 31, 2012 Placement Agent [Member] | Dec. 06, 2011 Advisory Firm [Member] | Dec. 31, 2013 Advisory Firm [Member]
Class of Warrant or Right [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advisory services fees |  |  | $ 12,500 |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  | $ 272,000 | $ 12,500 |
Percent of fully vested warrants to purchase common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  | 12.00% |
Exercise price per share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.50 |  |  | $ 0.01 |
Issuance of warrants to purchase common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,290,950 |  |  |  |
Issuance of warrants to purchase common stock description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants. |  |  |  |
Term of warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |
Maximum reimbursement expenses, monthly |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000
Proceeds from sale of Series A preferred stock |  |  |  | 3,494,428 | 3,220,018 |  |  |  |  |  |  |  |  |  |  | 3,089,500 | 554,700 | 470,300 |  |
Issuance of common stock to founder for cash | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock for services, Shares |  |  |  |  |  | 250,000 | 1,725,000 | 1,275,156 | 29,052 | 56,394 | 68,356 |  |  |  |  |  |  |  |  |
Issuance of common stock to acquire Medeor, Inc. at fair value, Shares |  | 17,089 |  |  |  |  |  |  |  | 2,500,000 |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  | 3,750,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of subordinated promissory notes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 68,400 | 25,100 |  |
Related party transaction, Description of Transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | In consideration for its services, the placement agent received: (a re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company's common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. | In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee. |  |  |  |  |
Offering price description |  |  |  |  |  |  |  |  |  |  |  |  | (a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000. |  |  |  |  |  |  |
Number of agreements |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Activation fee |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |
Business acquisition, Description |  |  |  |  |  |  |  |  |  |  |  |  |  | 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services. | 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services. |  |  |  |  |
Royalty payments description |  |  |  |  |  |  |  |  |  |  |  | (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product. |  |  |  |  |  |  |  |
Royalty received by licensee description |  |  |  |  |  |  |  |  |  |  |  | (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. |  |  |  |  |  |  |  |

X
- Definition Exercise price of the warrants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Article 12 -Section 13 -Sentence Column A + Details
Name: | invest_InvestmentWarrantsExercisePrice
Namespace Prefix: | invest_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Activation fee. + References No definition available. + Details
Name: | relm_ActivationFees
Namespace Prefix: | relm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Offering price. + References No definition available. + Details
Name: | relm_InvestorOfferingPriceDescription
Namespace Prefix: | relm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance of Warrants to Purchase Common Stock. + References No definition available. + Details
Name: | relm_IssuanceOfWarrantsToPurchaseCommonStock
Namespace Prefix: | relm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Issuance of Warrants to Purchase Common Stock. + References No definition available. + Details
Name: | relm_IssuanceOfWarrantsToPurchaseCommonStockDescription
Namespace Prefix: | relm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of agreements. + References No definition available. + Details
Name: | relm_NumberOfEngagementAgreement
Namespace Prefix: | relm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of vested warrants to purchase common stock. + References No definition available. + Details
Name: | relm_PercentageOfVestedWarrantsToPurchaseCommonStock
Namespace Prefix: | relm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement expenses. + References No definition available. + Details
Name: | relm_ReimbursementExpenses
Namespace Prefix: | relm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of Royalty Payments. + References No definition available. + Details
Name: | relm_RoyaltyPaymentsDescription
Namespace Prefix: | relm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Received by Licensee Description. + References No definition available. + Details
Name: | relm_RoyaltyReceivedByLicenseeDescription
Namespace Prefix: | relm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of warrants. + References No definition available. + Details
Name: | relm_TermOfWarrants
Namespace Prefix: | relm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of equity interests issued or issuable to acquire the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from a borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in liquidation of the entity's assets or underlying collateral. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849 + Details
Name: | us-gaap_ProfessionalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6452652&loc=d3e36975-112693 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 2 -Article 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.10,11,23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 10, 11, 23 -Article 5 + Details
Name: | us-gaap_RelatedPartyTransactionDescriptionOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration